Octagam (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Octagam, is an immunoglobulin presented as a 10% solution for intravenous use. It replaces deficient antibodies and is used in primary immunodeficiency disorders and certain autoimmune conditions in both children and adults.

GNH USA supplies Octagam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Octagam is an immunoglobulin therapy that modulates immune function in several clinical settings. - Primary immunodeficiency diseases: provides essential antibodies to reduce infection frequency. - Chronic inflammatory demyelinating polyneuropathy (CIDP): helps restore nerve function and lessen disability. - Multifactorial immune thrombocytopenia (ITP): raises platelet counts and decreases bleeding risk.

Adverse reactions to Octagam vary from mild to severe and are monitored throughout therapy.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Fever or chills: typical infusion‑related response. - Nausea or vomiting: usually resolves after the infusion ends. - Fatigue: general tiredness during or after administration. - Injection site erythema: localized redness at the catheter site. - Hypertension: temporary rise in blood pressure during infusion.

Serious or Rare Side Effects: - Anaphylaxis: acute, life‑threatening allergic reaction requiring immediate medical intervention. - Acute renal failure: sudden loss of kidney function, especially in patients with pre‑existing renal disease. - Thromboembolic events: clot formation that can affect veins or arteries. - Hemolytic anemia: destruction of red blood cells leading to anemia. - Aseptic meningitis: inflammation of the meninges without infection. - Severe transfusion‑related acute lung injury (TRALI): acute respiratory distress following infusion.

Before initiating Octagam therapy, clinicians should evaluate patient history and monitor for specific risks. - Assess renal function: baseline creatinine and eGFR are required. - Screen for thrombotic risk: consider history of clotting disorders. - Evaluate for IgA deficiency: patients with anti‑IgA antibodies may develop severe reactions. - Monitor blood pressure: watch for hypertension during infusion. - Observe for signs of infection: ensure active infections are treated before infusion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other agents that affect immune function or coagulation.

Major Interactions (Avoid): - Live vaccines: concurrent administration can reduce vaccine efficacy and increase adverse events. - High‑dose aspirin or anticoagulants: heightened risk of bleeding complications.

Moderate Interactions (Monitor Closely): - Immunosuppressive biologics (e.g., rituximab): may alter therapeutic response. - Corticosteroids: can increase infection risk when combined. - ACE inhibitors: may potentiate infusion‑related hypertension. - Diuretics: monitor fluid balance and renal function. - Antiviral agents (e.g., ganciclovir): watch for additive nephrotoxicity.